1. Ontario Ministry of Health (2008) Ontario Drug Benefit Formulary/Comparative Drug Index No. 41. Queen’s Printer for Ontario, Toronto
2. Tilson L, Barry M (2005) European pharmaceutical pricing and reimbursement strategies. National Centre for Pharmacoeocnomics, Dublin, Ireland, p 166
3. Taylor RS et al. (2004) Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ 329:972–975
4. OECD (2005) Drug spending in OECD countries up by nearly a third since 1998, according to new OECD data.
http://www.oecd.org/document/25/0,2340,en_2649_201185_34967193_1_1_1_1,00.html
. Accessed 15 Nov 2011
5. OECD (2011) Quarterly National Accounts MetaData: Quarterly Growth Rates of real GDP, change over previous quarter.
http://www.oecd.org/document/25/0,2340,en_2649_201185_34967193_1_1_1_1,00.html
. Accessed 23 Nov 2011